公开(公告)号：US20200206185A1

公开(公告)日：2020-07-02

申请号：US16612219

申请日：2018-05-09

申请人： Vitality Biopharma, Inc.

发明人： Brandon Joel Zipp ,  Robert Thomas Brooke

IPC分类号： A61K31/352 ,  A61K31/05 ,  A61K9/00 ,  A61P31/04

摘要： The invention relates is directed to antimicrobial compositions comprising cannabinoid compounds and methods of utilizing the antimicrobial compositions to inhibit the growth of microorganisms, to treat and/or prevent microbial infections.

公开(公告)号：US20190125702A1

公开(公告)日：2019-05-02

申请号：US16084086

申请日：2017-03-13

申请人： Vitality Biopharma, Inc.

发明人： Tassie Collins ,  Karen Lariosa-Willingham ,  Jason Dugas ,  Jay S. Tung ,  Dmitri Leonoudakis ,  Elen Rosler

IPC分类号： A61K31/165 ,  A61K45/06 ,  A61P25/00 ,  A61P37/06

摘要： The present invention provides methods and compositions for repairing and/or maintaining the myelin sheath of neuronal axons in a subject. In particular, the present invention provides compositions comprising one or more TRPV1 agonists exhibiting promyelinating activity for treatment of demyelinating disorders.

公开(公告)号：US20180264122A1

公开(公告)日：2018-09-20

申请号：US15762180

申请日：2016-09-22

申请人： Vitality Biopharma, Inc

发明人： Brandon J. Zipp ,  Janee M. Hardman ,  Robert T. Brooke

IPC分类号： A61K47/54 ,  A61K31/352

CPC分类号： A61K47/549 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/352 ,  A61K31/7012 ,  A61K31/7016 ,  A61K31/7034 ,  A61P1/10 ,  A61P25/00 ,  A61P29/00 ,  C07H15/10 ,  C07H15/203

摘要： The present invention relates to cannabinoid glycoside prodrugs suitable for site- and tissue-specific delivery of cannabinoid molecules. The present invention also relates to methods of forming the cannabinoid glycoside prodrugs through glycosyltransferase mediated glycosylation of cannabinoid molecules.

公开(公告)号：US10533205B1

公开(公告)日：2020-01-14

申请号：US14511103

申请日：2014-10-09

申请人： Vitality Biopharma, Inc.

发明人： Brandon Zipp

IPC分类号： C07H15/18 ,  A61K31/704 ,  C07H13/08 ,  A61K31/7028 ,  C12P19/44 ,  C12P19/56

摘要： Ent-kaurenoic acid glycoside precursor compositions and synthesis methods are provided. The KA-19-monoside, KA-19-bioside and KA-19-trioside precursors can be used as starting materials for a variety of kaurenoic acid based reactions. The precursors provide alternative synthesis pathways for steviol glycosides to the natural pathway based on Steviol biosynthesis. The alternative synthesis pathways using the precursors also circumvent the rate limiting step of the natural Steviol biosynthesis pathway. The precursors can be used individually or in combination to produce a mixture or individual steviol glycosides such as Rebaudioside A, Rebaudioside D or Rebaudioside M. Control over the precursor quantities and composition allows control over the composition of the resulting steviol glycosides that are finally produced.